Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients

Clinical trial NCT03194867 · COMPLETED

Trial details

NCT number: NCT03194867
Sponsor: Sanofi
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Plasma Cell Myeloma

Start date: 2018-02-21
Primary completion: 2023-04-05
Enrollment: 109

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.